<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

SmartTRAK Life Sciences News and Analysis Blog in the Orthopedics, Wound, and Neuro Therapies Market Segments

Regenerative Medicine

AAOS 2019: An Interview with OrthogenRx CEO Michael Daley

OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc...

SmartTRAK News

Meet SmartTRAK's Elise Wolf at CAOS 2019 in New York City

Elise Wolf, SmartTRAK's Senior Analyst, Computer Assisted Surgery, will be representing SmartTRAK at CAO...

SmartTRAK News

Meet SmartTRAK's Freddy Buntoum at TOBI 2019 in Chicago

Frederique Buntoum (aka Freddy), SmartTRAK's Senior Analyst, Regenerative Medicine, overseeing the Cell ...

Wound Care

3M/Acelity: A Deeper Look Into the Potential Deal

SmartTRAK examines what the combined company will look like in terms of revenue, product portfolios, fin...

Wound Care

Artificial Intelligence for DFUs: An Interview with Dr. Ronald Baxter of Spectral MD

Dr. Ronald Baxter of Baylor University and Spectral MD, discusses the Spectral MD DeepView Wound Imaging...

Orthopedics

Q119 Total Joints Recap: Market Benefits from Easier Comps

As surgeries get pushed to later in the year, growth against easier comps does not signal market strengt...

Orthopedics

AAOS 2019: Arthrosurface Working to Stand Out in Shoulder Arthroplasty market

SmartTRAK interviews Arthrosurface CEO Steve Ek about the Company’s newest shoulder system, the OVOMotio...

Wound Care

SmartTRAK Seeking a European Wound Care Analyst

The SmartTRAK analyst team is expanding and we are looking for an experienced and motivated individual w...

Neuro Therapies

Intraoperative Neuromonitoring in SCS: An Interview with Steven Falowski, MD

Intraoperative neuromonitoring could be a game changer in the field of SCS by elucidating the MOA for cu...

Orthopedics

Q119 Joint Fluid Market: Revenues Down, Pricing Pressures and FDA Scrutiny

Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny After a sluggish...

1
...
69 70 71
...
96